Significant differences exist when analyzing cancer treatment approaches in the United States and Western Europe. The American model, generally characterized by for-profit insurance and a priority on innovation, often leads to swift adoption of cutting-edge therapies, albeit at a significantly higher cost. In contrast, European systems frequently r